IRMD trades 17.1% below Wall Street's consensus target of $100.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IRMD achieves its forward estimates and maintains a stable P/E multiple of 40.4x. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, IRadimed Corporation (IRMD) has a Wall Street consensus price target of $100.00, based on estimates from 2 covering analysts. With the stock currently trading at $85.40, this represents a potential upside of +17.1%. The company has a market capitalization of $1.09B.
Analyst price targets range from a low of $60.00 to a high of $120.00, representing a 60% spread in expectations. The median target of $120.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, IRMD trades at a trailing P/E of 48.8x and forward P/E of 40.4x. The forward PEG ratio of 0.55 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +18.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $98.86, with bear and bull scenarios of $62.28 and $130.26 respectively. Model confidence stands at 48/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LNTHLantheus Holdings, Inc. | $6.5B | $99.96 | $104.48 | +4.5% | Buy | 18.5x | 19 |
 PRCTPROCEPT BioRobotics Corporation | $977M | $17.16 | $22.13 | +29.0% | Buy | — | 16 |
 ANGOAngioDynamics, Inc. | $625M | $15.11 | $19.50 | +29.1% | Hold | — | 11 |
 NVCRNovocure Ltd | $1.7B | $14.94 | $26.00 | +74.0% | Buy | — | 15 |
 GEHCGE HealthCare Technologies Inc. | $29.0B | $64.29 | $79.92 | +24.3% | Buy | 13.1x | 18 |
 STESTERIS plc | $20.3B | $208.54 | $271.33 | +30.1% | Buy | 20.5x | 14 |
 MMSIMerit Medical Systems, Inc. | $5.1B | $85.37 | $101.88 | +19.3% | Buy | 19.8x | 15 |
 INVAInnoviva, Inc. | $1.5B | $20.50 | $38.00 | +85.4% | Buy | 8.5x | 10 |
 ATECAlphatec Holdings, Inc. | $1.5B | $10.03 | $16.22 | +61.7% | Buy | 30.7x | 20 |
 SYKStryker Corporation | $105.6B | $275.43 | $370.16 | +34.4% | Buy | 18.4x | 52 |
Quick answers to the most common questions about buying IRMD stock.
IRadimed Corporation (IRMD) has a consensus 12-month price target of $100, implying 17.1% upside from $85.4. The 2 analysts covering IRMD see moderate appreciation potential.
IRMD has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $100 implies 17.1% upside from current levels.
At a forward P/E of 40.4107x, IRMD trades at a premium valuation. The consensus price target of $100 (17.1% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $120 for IRMD, while the most conservative target is $60. The consensus of $100 represents the median expectation. Our quantitative valuation model projects a bull case target of $130 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
IRMD is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IRMD stock forecast based on 2 Wall Street analysts shows a consensus price target of $100, with estimates ranging from $60 (bear case) to $120 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $99, with bear/bull scenarios of $62/$130.
Our quantitative valuation model calculates IRMD's fair value at $99 (base case), with a bear case of $62 and bull case of $130. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 48/100.
IRMD trades at a forward P/E ratio of 40.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 48.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on IRMD, with a "Buy" consensus rating and $100 price target (17.1% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IRMD analyst price targets range from $60 to $120, a 60% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $100 consensus represents the middle ground. Our model's $62-$130 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.